EUCTR2013-003002-91-IT进行中（未招募）1 期
Pilot study on efficacy and safety of bilastine in preventing angioedema attacks in patients with recurrent angioedema of unkown etiology (idiopatic angioedema, rIAE) - Right
Menarini International Operation Luxembourg SA0 个研究点目标入组 50 人开始时间: 2013年8月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Subjects must have given a written informed consent;
- •2.Male or female;
- •3.Age = 18 years;
- •4.Diagnosis of recurrent IAE (according to Kaplan-Greaves 2005 criteria - Annex )
- •5.History of = 9 days of moderate to severe cutaneous or mucosal angioedema during the last 12 weeks;
- •6.C1-inhibitor functional levels = 60% of normal values;
- •7.Able to complete screening and assessments;
- •8.Women of childbearing potential must have a negative urine pregnancy test;
- •9.Willingness and ability to participate in the study;
- •10.No other experimental treatments;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.Diagnosis of angioedema of any defined cause: allergic, hereditary/acquired C1-Inhibitor deficiency, ACE (Angiotensin Converting Enzyme) inhibitor or NSAID induced angioedema, drug and/or food/disease induced angioedema (according to Kaplan-Greaves 2005 criteria);
- •2.Participation in a clinical trial of another Investigational Product (IP) within the past month;
- •3.Chronic use within the last 3 month before recruitment of systemic or topical corticosteroids, any other systemic antihistamine, anti-leukotrienes, sodium cromoglycate or nedocromil, tricyclic antidepressants, ACE-inibhitors, ARB (Angiotensin Receptor Blockers), tranexamic acid, with the exception of the case in which some of them have been used for the angioedema attacks.
- •4.Use of antihistamines or corticosteroids within the week prior to study randomization.
- •5.Evidence of clinically relevant or chronic disease or condition that upon the judgment of the investigator contraindicates participation to the study (eg history of autoimmune disorders, Hodgkin’s disease, cardiovascular, neurological, hepatic, renal or malignant diseases);
- •6.Pregnancy and/or breast-feeding;
- •7.Mental condition rendering the subject, in the opinion of the investigator, unable to understand the nature, scope and possible consequences of the study;
- •8.Unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason;
- •9.Known hypersensitivity to bilastine, its excipients, H1-antihistamines, benzimidazoles
研究者
相似试验
进行中（未招募）
1 期
Pilot study on efficacy of bilastine in preventing angioedema symptoms in patients with angioedema of unknown etiology (idiopathic angioedema, IAE)EUCTR2012-005824-13-ITMenarini International Operation Luxembourg SA50
尚未招募
4 期
Safety and Effectiveness of Bilastine and Fexofenadine in Perennial Allergic Rhinitis patientsCTRI/2024/07/071414Teerthanker Mahaveer Medical College and Research Centre Moradabad
已完成
3 期
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With BilastineSeasonal Allergic RhinitisNCT01108783Faes Farma, S.A.720
已完成
3 期
Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic RhinitisSeasonal Allergic RhinitisNCT01400828Yuhan Corporation239
进行中（未招募）
不适用
A clinical phase I / II trial of Belinostat in combination with Erlotinib in patients with non-small cell lung cancer.Metastatic non small lungcancerEUCTR2009-018205-43-DKOncology Department35